Notwithstanding promising clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable resistance from PBMs. The insurers are often building limitations to coverage, like steep price criteria and prior authorization that h